Nautilus Biotechnology, Inc. (NASDAQ: NAUT) issued a press release on October 27, 2026, detailing its financial performance and business developments for the third quarter ended September 30, 2026. The company reported total revenue of $0.2 million for the quarter, a figure driven entirely by grant revenue from the Michael J. Fox Foundation and service revenue generated through its Iterative Mapping Early Access Program.
Operating expenses for the quarter totaled $16.9 million, representing a 10% increase compared to the prior year period. This rise was attributed to higher costs for laboratory and professional services, as well as increased salaries and related benefits, which were partially offset by lower facilities expenses. Consequently, the company recorded a net loss of $15.6 million for the three months ended September 30, 2026, compared to a net loss of $13.6 million in the same period of the prior year.
As of September 30, 2026, Nautilus reported cash, cash equivalents, and investments of $114.3 million. The company also highlighted several key business milestones, including the publication of a peer-reviewed paper in Nature Methods regarding its Iterative Mapping technology and the presentation of initial development data on oncology proteoform assays at World HUPO 2026.
Subsequent to the quarter's end, Nautilus announced its participation in the SEEDS consortium, a four-year research initiative funded by ARPA-H. The company expects to receive up to $6 million to utilize its Voyager Platform to measure proteoforms associated with Alzheimer’s disease and cancer.
